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Xenograft modelsGlioblastoma (GBM) is the most frequent and malignant form of primary brain tumor. GBM is essentially incur-
able and its resistance to therapy is attributed to a subpopulation of cells called glioma stem cells (GSCs). Tomeet
the present shortage of relevant GBM cell (GC) lines we developed a library of annotated and validated cell lines
derived from surgical samples of GBMpatients,maintained under conditions to preserveGSC characteristics. This
collection, which we call the Human Glioblastoma Cell Culture (HGCC) resource, consists of a biobank of 48 GC
lines and an associated database containing high-resolution molecular data. We demonstrate that the HGCC
lines are tumorigenic, harbor genomic lesions characteristic of GBMs, and represent all four transcriptional sub-
types. The HGCC panel provides an open resource for in vitro and in vivomodeling of a large part of GBMdiversity
useful to both basic and translational GBM research.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The prognosis for glioblastoma (GBM), the commonest primaryma-
lignant brain tumor in adults (Dolecek et al., 2012) is poor with a 1-year
survival rate of 36.5% (Ostrom et al., 2014). Standard treatment involves
surgery to remove as much of the tumor as possible, followed by com-
bined radiation and chemotherapy with temozolomide (Stupp et al.,
2005). GBM is characterized by pronounced invasiveness, as well as ex-
tensive intra- and inter-tumor heterogeneity (Patel et al., 2014;
Sottoriva et al., 2013; Verhaak et al., 2010).
Transcript proﬁling in combination with analysis of genomic aberra-
tions have revealed distinct molecular subtypes of GBM (Brennan et al.,
2013; Phillips et al., 2006; Verhaak et al., 2010). The most commonly
used classiﬁcation is that presented by The Cancer Genome Atlas Re-
search Network (TCGA), which describes four subtypes (Verhaak et al.,
2010), i.e. Proneural, Classical, Mesenchymal and Neural GBM. Theser), lene.uhrbom@igp.uu.se
. This is an open access article underare deﬁned primarily on the basis of their particular transcriptional sig-
natures but can be associated, at least statistically,with distinctive genet-
ic aberrations. Proneural tumors exhibit a higher frequency of PDGFRA or
IDH1 mutations, as well as a G-CIMP+ (glioma-CpG island methylator
phenotype) subgroup that displays global hypermethylation, which
overlaps with IDH1mutations. Patients with G-CIMP+ tumors are youn-
ger at the time of diagnosis and have a survival advantage (Brennan
et al., 2013; Noushmehr et al., 2010). Classical tumors demonstrate
high rates of EGFR ampliﬁcation and homozygous deletions of CDKN2A;
mesenchymal samples often harbor hemizygous deletions of NF1;
whereas no distinctive mutations have yet been found in neural GBMs.
Subtyping is complicated by the pronounced intratumor heterogeneity
and different regions of one and the same tumor can be classiﬁed differ-
ently (Sottoriva et al., 2013). In addition, single-cell sequencing of cells
from ﬁve patients has revealed amixture of subtypes even at the cellular
level in each individual patient (Patel et al., 2014).
There is a high demand for readily available and relevant cell models
of GBM. For 30 years, several GC lines, including U87 (N1900 citations in
PubMed), U251 (N1100 citations) and T98G (N900 citations), have been
employed extensively in this context, providing valuable knowledge
about this type of tumor. However, these models are imperfect for sev-
eral reasons. First, the serum-containing medium in which thesethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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transcriptomes and causes depletion of stem cell-like tumor cells (Lee
et al., 2006). Secondly, tumors formed by injection of such cell lines
into the brains of mice fail to develop the deﬁning morphological fea-
tures of GBM, such as diffuse inﬁltration into surrounding healthy tissue
and microvascular proliferations (Lee et al., 2006; Mahesparan et al.,
2003; Pontén and Macintyre, 1968; Westermark et al., 1973). And
third, the lack of systematic clinical characterization of the tumors
fromwhich the current GC lines derive makes it impossible to correlate
ﬁndings with these models to patient parameters.
There is ample evidence that a minor subset of GBM cells (GCs), de-
noted glioblastoma stem cells (GSCs) are likely responsible for relapse
because they possess a unique capacity for growth and progression
(Beier et al., 2007; Galli et al., 2004; Lathia et al., 2010; Ogden et al.,
2008; Singh et al., 2004; Son et al., 2009) and are particularly resistant
to therapy (Bao et al., 2006; Bleau et al., 2009; Chen et al., 2012). Re-
search designed to improve GBM culture conditions has shown that
GSCs can be readily cultured as spheres, utilizing the same conditions
as for normal neural stem cells (Hemmati et al., 2003; Ignatova et al.,
2002; Singh et al., 2003). Moreover, orthotopical transplantation of
such spheres into mice generated secondary tumors that retained the
features of the primary tumor (Galli et al., 2004), which was also the
case after injection of adherent cultures of GSC (Fael Al-Mayhani et al.,
2009; Pollard et al., 2009). Recent extensive work characterizing
orthotopic xenograft models showed that acutely transplanted patient-
derivedGCsmimickedwell thehistopathology, genomics andphenotyp-
ic properties of the corresponding patient's primary tumor (Joo et al.,
2013). This study provides an important platform for accurate in vivo
modeling of GBM but cannot fully meet the need for cell-based models.
Since GSCs cultured under stem cell conditionsmore accuratelymir-
ror GBM biology and because such models are increasingly in demand,
we have created a novel library of well-characterized GC cultures that
we make publicly available here. We describe the establishment and
characterization of 48 sustainable GC lines, derived from Swedish pa-
tients during the period of 2009–2012, and including all four molecular
subtypes, a biobank we refer to as the Human Glioblastoma Cell Culture
(HGCC) resource. This information, along with clinical variables, is also
available online (www.hgcc.se). The utility of this database is reﬂected
in the fact that several of these cell lines have already been shared and
used to discover a novel potent candidate drug for treatment of GBM
(Kitambi et al., 2014), as well as in a number of other studies (Wee
et al., 2014; Babateen et al., 2015; Schmidt et al., 2013; Savary et al.,
2013; Yu et al., 2013).
2. Materials & Methods
2.1. GBM Patients and Glioma Cell Cultures
Surgical specimens and clinical records for 102 adult patients with
glioma were obtained from Uppsala University Hospital in accordance
with protocols approved by the regional ethical review board and after
obtaining written consent by all of the patients. Most of the tumor spec-
imens were obtained directly from the operating theater, but in some
cases from Clinical Pathology. Following World Health Organization
(WHO) guidelines (Louis et al., 2007) neuropathologists classiﬁed the
tumors as grades II–IV. The surgical samples were rendered anonymous
and coded. A piece of eachwas stored at−70 °C for later RNA extraction
and another piece ﬁxedwith formalin and embedded in parafﬁn for his-
tological analysis. The remainder of the specimen was explanted as de-
scribed in detail in the Extended Experimental Procedures.
2.2. Analysis of Global Gene Expression and Classiﬁcation of the Molecular
Subtype of the GC Lines
Total RNA extracted from 48 GC lines using the RNeasy Mini kit
(Qiagen) was labeled and hybridized on Affymetrix GeneChip HumanExon 1.0 ST arrays. Expression levels were RMA-normalized employing
the Affymetrix Expression Console software. The GC lines were classi-
ﬁed with the k-nearest neighbor approach, and bootstrap aggregation
in which the classiﬁcation was repeated 1000 times, each time using a
subsampled version of the TCGA dataset (529 randomly selected
cases, sampled with replacement from the original dataset). Isomap
analysis was applied to visualize the GC lines and TCGA samples in
two dimensions. The details of data analysis are provided in the Extend-
ed Experimental Procedures. Expression data is made available viaNCBI
Gene Expression Omnibus (GSE72217) and hgcc.se.
2.3. Analysis of Gene Expression by NanoString Technology and Assignment
of a Subtype to the Surgical Samples and GC Lines
To determinemolecular subtypes, RNA extracted from22 specimens
of fresh frozen human glioma using TRIzol and from the corresponding
GC lines in the samemanner as described above, was used in a custom-
made assay by NanoString Technology. For further details, see the Ex-
tended Experimental Procedures.
2.4. Proliferation Assay
The proliferation of 13 GC lines was assessed by the AlamarBlue
assay (Invitrogen) and that of 18 other lines by Trypan blue exclusion
on Countess Cell Counting Chamber Slides (Invitrogen). See the Extend-
ed Experimental Procedures for additional details.
2.5. Analysis of the In Vivo Tumorigenicity of the GC Lines
All animal experiments were performed in accordance with the
rules and regulations of Uppsala University and approved by the local
animal ethics committee. Neonatal non-obese diabetic-severe com-
bined immunodeﬁciency (NOD-SCID) mice (P1–3) were injected intra-
cerebrally with 1.0 × 105 human GCs, as summarized in Table S6. The
mice were sacriﬁced when they showed symptoms or otherwise
20 weeks after injection and their brains were analyzed for xenograft
tumors. See the Extended Experimental Procedures for additional
details.
2.6. Analysis of Aberrations in DNA Copy Number
DNA isolated from 48 GC lines using the DNeasy blood and tissue kit
(Qiagen) was proﬁled on Affymetrix Cytoscan arrays at the Uppsala Ac-
ademic Hospital Array and Analysis facility, in accordance with the
manufacturer's instructions. Identiﬁcation of segments carrying altered
numbers of copies was achieved with the Patchwork R package
(Mayrhofer et al., 2013), which quantiﬁes the log-relative change in
DNA content for each chromosomal region. CNA data is made available
viaNCBIGene ExpressionOmnibus (GSE72209) and hgcc.se. See the Ex-
tended Experimental Procedures for additional details.
2.7. Subtype Stability In Vitro and In Vivo
RNA was prepared from cells and tumor tissue and analyzed on the
Affymetrix HTA 2.0 platform. See the Extended Experimental Proce-
dures for additional details. Expression data is made available via NCBI
Gene Expression Omnibus (GSE72218) and hgcc.se.
2.8. Statistical Analyses
The unpaired t-test was used for comparison of two groups, a one-
way ANOVA for comparison of more than two groups; and the
log-rank test for survival curves. Statistical signiﬁcance was deﬁned as
p ≤ 0.05. Cox regression was performed using the package rms in
R 3.1.2. All statistical analyses were carried out with the GraphPad
Prism6.0 software.
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3.1. The Cohort of Patients and In Vitro Cell Cultures
From 101 patients (including 13 duplicate samples from the same
individuals and 9 relapse samples) who underwent surgery for
suspected high-grade glioma, 114 surgical specimens were explanted
(Table S1). Following dissociation, the tumor cells were ﬁrst cultured
as spheres in deﬁned serum-free media and after 5–7 days transferred
to laminin-coated dishes for further propagation as adherentmonolayer
cultures. In connectionwith both of these steps, the pattern of growth of
cells from different patients varied extensively. Most of the primary cell
cultures did not readily form spheres, but instead formed smaller aggre-
gates of cells, many of which could still be effectively expanded on lam-
inin. Most cultures that ceased to grow did so early in the process,
usually not even producing an adherent culture that could be subjected
to the ﬁrst passage. After a culture had undergone 8–10 passages and
continued to proliferate, it was considered a sustainable GC line. Many
have now undergone 20 passages or more. From 94 GBM surgicalFig. 1. The GBM patient cohort: Molecular diversity and correlations between establishment o
GBM fromwhomsustainable cell lines could (solid line) and could not (dotted line) be establish
patients (71–82 years old, average 74) are above the third quartile, the intermediate ones (57–70
48) below theﬁrst quartile. Log-rank test, **p b 0.01. (C) Age distribution of thepatients fromwh
be established. Student's t-test, **p b 0.01. (D) Isomap analysis of 48 GC lines and 529 TCGA tisspecimens (82 patients) 53 GC lines were established. Two parallel
lines were produced from each of two GBM patients (U3084MG and
U3086MG; U3117MG and U3118MG), and one (U3054MG) was
established from a GBM that recurred after the patient had undergone
surgery and radiotherapy (50.4 Gy in total). We also established one
cell line from a grade III tumor but none from grade II tumors.
Here, we describe 48 of the GBM-derived GC lines obtained
(Table S2). Initially, for identiﬁcation and future authentication,multiplex
short tandem repeat (STR) proﬁling was performed on most of these
(Table S2, Table S3). The ability of GCs to form renewable neurospheres
has been correlated to shorter GBM patient survival (Laks et al., 2009).
To evaluate if also the ability of GCs to bemaintained as adherent cultures
could be a predictor of survival we compared patients fromwhich one or
more GC lines could be established to those from which no cell line was
produced. We found a signiﬁcant correlation between successful estab-
lishment of a GC line froma patient's tumor and a shorter patient survival
(Fig. 1A). It is well established that age at the time of diagnosis is a major
determinant of GBM patient survival (Brennan et al., 2013) and to inves-
tigate if this also holds true for our patient cohort all GBM patients weref GC lines, survival and age. (A) Kaplan–Meier comparison of the survival of patients with
ed. Log-rank test, *p b 0.05. (B) Kaplan–Meier comparison of survival versus age. The oldest
, average 64) betweenﬁrst and third quartiles, and the youngest (21–56 years old, average
oma sustainableGC line could (average age 66years) and could not (average age 59 years)
sue samples of known molecular subtypes.
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the youngest patients below the ﬁrst quartile, the intermediate patients
between the ﬁrst and third quartiles, and the oldest patients above the
third quartile. As expected, our younger GBM patients survived signiﬁ-
cantly longer (Fig. 1B). The age of patients from whose tumors a GC line
could be established was signiﬁcantly higher (Fig. 1C), and, accordingly,
a Cox multivariate analysis of both these parameters (ability to be prop-
agated in culture and age) showed that only agewas a signiﬁcant predic-
tor of survival. This is an interesting observation and could indicate that
shorter survival in the older population is due to inherentlymore aggres-
sive tumor cells rather than factors such as differences in the extent of re-
section or type of treatment, although the inﬂuence by changes in the
microenvironment due to aging cannot be excluded.
3.2. Subtyping of the GC Lines and Tumor Samples From Which They
Were Derived
Global gene expression (employing Affymetrix GeneChip Human
Exon 1.0ST Arrays) followed by subtype classiﬁcation was performedFig. 2.Molecular subtyping of GC lines and their corresponding tumor samples. (A) Forty-eigh
subtyping (indicated to the right of each bar) by applying a k-nearest neighbor classiﬁcation in
siﬁed asMesenchymal (MS, red bars), Neural (NL, green bars), Proneural (PN,magenta bars) or
of each GC line is indicated to the right of each bar. * = sample that failed to be analyzed on th
scriptome Array (see Fig. 7B). (B) Comparison of the predicted subtypes of 22 GC lines and the
The fraction of times each cell line or tissue sample was assigned to theMesenchymal (MS, red
type is depicted and the ﬁnal assignment indicated to the right or left of the bars, respectively.on 48 of the GC lines. In a ﬁrst unsupervised analysis we combined
z-scores for mRNA expression levels for 765 subtype classiﬁcation
genes (Verhaak et al., 2010) across 529 TCGA tissue samples and our
48GC lines, andmapped them into a 2-dimensional space using Isomap,
a dimensionality reduction technique applicable to grouping of cancer
samples (Nilsson et al., 2004; Tenenbaum et al., 2000). The resulting
Isomap (Fig. 1D) conﬁrmed a clear separation of the Classical,
Mesenchymal and Proneural TCGA subtypes and showed that our GC
lines with similar transcriptional proﬁles were interspersed among
them, suggesting that these three subtypes are well represented in
our collection.
We then classiﬁed each individual GC line as Proneural, Classical,
Mesenchymal or Neural using the TCGA cohort of GBM (n = 529) as a
reference. For this purpose, we applied a supervised classiﬁcationmeth-
od, the k-nearest neighbor algorithm (KNN) to assign each line to a class
(Fig. 2A). To assess the stability of these assignments we utilized statis-
tical bootstrapping (James et al., 2013); applied in this context,
bootstrapping means that we repeated the classiﬁcation 1000 times
for each cell line, each time using a subsampled version of the TCGAt GC lines were analyzed by Affymetrix GeneChip Human Exon 1.0ST Arrays, followed by
combination with bootstrapping. The variation in the fraction of times each cell line clas-
Classical (CL, blue bars) reﬂects the uncertainty of the assignment. The subtype assignment
e Exon Array, the assigned subtype is based on gene expression analyzed on Human Tran-
corresponding tumor tissue based on gene expression analysis by NanoString Technology.
bars), Neural (NL, green bars), Proneural (PN, purple bars) or Classical (CL, blue bars) sub-
See also Table S2.
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lines were assigned to the same classiﬁcation at least 90% of the time
(i.e. same subtype in at least 900 out of 1000 bootstrap simulations),
whereas the classiﬁcation of the remaining 10 varied. For instance,
U3033MG was classiﬁed as intermediate between Classical and
Proneural (Fig. 2A). Overall, the distribution of the cell lines between
different subtypes was similar to the TCGA analysis of tumor tissue
(Verhaak et al., 2010) with the most being Mesenchymal, followed by
Classical, Proneural, and Neural in that order. The cell lines derived
from two separate samples from the same patient (U3084MG and
U3086MG; U3117MG and U3118MG) were of the same subtype. The
cell line derived from a recurrent GBM (U3054MG) was classiﬁed as
Mesenchymal.
For one subset of samples (n= 22) we analyzed the molecular sub-
type of both the primary tumor and the corresponding GC line (Fig. 2B).
Since the tissue RNA was too degraded (due to long handling times in
connection with surgery) for microarray hybridization, we assessed
gene expression employing NanoString Technology and a custom set
of probes (Table S4) designed by Drs. Cameron Brennan and Jason
Huse at the Brain Tumor Center, Memorial Sloan-Kettering Cancer
Center (Kastenhuber et al., 2014). In 10 cases the tissue and correspond-
ing GC line were of the same subtype. The differences in the remaining
12 cases could have many causes, including intratumoral heterogeneity
(Patel et al., 2014; Sottoriva et al., 2013) and clonal selection duringFig. 3. Proliferation capacity of GC lines in relation to subtype and survival. (A) Kaplan–Meier c
lines established from their tumors. (B) Growth curves for 31 GC lines of differing TCGA molec
quartile were designated as “low proliferation”, between the ﬁrst and third quartiles as “inte
lines categorized were listed in the order of highest to lowest proliferative capacity. (D) Analy
molecular subtype. (E) Kaplan–Meier plot comparing the survival of patients with GBM in rel
GC lines. Log-rank test, *p b 0.05.culturing (Meyer et al., 2015). The slight discrepancy of 23% in classiﬁca-
tion of GC lines when comparing the results from the Affymetrix and
NanoString Technology approaches probably reﬂects the different
gene signatures used. This difference is modest and as a benchmark
we also classiﬁed the TCGA GBM samples for which there were data
from two different platforms (Affymetrix and Agilent), which showed
a discrepancy of 29% between the two platforms although the same
gene signaturewas used in this case (Fig. S1). Altogether, these analyses
demonstrate that much of the inter-tumoral GBM heterogeneity can be
modeled by using neural stem cell culture conditions. The subtype that
we ﬁnally assigned each GC line and use hereafter is based on the
Affymetrix array (Fig. 2A).
Molecular subtyping of GBM tissue has proven to be of only limited
value in predicting patient survival, with the most striking difference
being a less favorable survival 15 months after diagnosis for patients
with G-CIMP+ and IDH1 mutated Proneural GBM in comparison to all
other GBM patients (Brennan et al., 2013). Analysis of our patients re-
vealed a trend towards worse survival among patients from whose tu-
mors GCs of the Proneural subtype were obtained (Fig. 3A). This
observation suggests that most of our Proneural GC lines were derived
from GBMs carrying wildtype IDH1, in line with a previous report that
showed that G-CIMP+ GCs survive poorly under deﬁned culture condi-
tions (Balvers et al., 2013). Indeed, exome sequencing of our cell lines
did not detect any mutations at codon R132, the most frequentlyomparing the survival of patients in relationship to the TCGAmolecular subtype of the GC
ular subtypes. Based on their proliferative capacity on day 7, the cell lines below the ﬁrst
rmediate proliferation”, and above the third quartile as “high proliferation”. (C) The GC
sis (Student's t-test) of the proliferative capacity of GC lines in relationship to their TCGA
ationship to the proliferative capacity (high, intermediate, and low) of the corresponding
1356 Y. Xie et al. / EBioMedicine 2 (2015) 1351–1363mutated site in the IDH1 (Weller et al., 2011) (Table S1, Table S5), indi-
cating that all of our lines are G-CIMP− (Noushmehr et al., 2010).
3.3. A Low Rate of Proliferation Predicts Better Survival
We evaluated the growth rates of 31 GC lines bymeasuring cell den-
sity and normalized the results from days 4 and 7 to that on day 1
(Fig. 3B). On the basis of their proliferative capacity on day 7, cell lines
below the ﬁrst quartile were designated “low proliferation”, between
the ﬁrst and third quartiles “intermediate proliferation”, and above the
third quartile “high proliferation” (Fig. 3B), and the cell lines in these
groups are listed from the highest to the lowest proliferative capacity
in Fig. 3C. The Proneural GC lines grew more rapidly than the other
three subtypes, while the Classical lines grew most slowly (Fig. 3D).
Moreover, we found that patients whose tumors gave rise to GC lines
designated “low proliferation” exhibited signiﬁcantly better survival
than the “high” and “intermediate proliferation” groups (Fig. 3E),
which were similar in this respect. There was no signiﬁcant difference
in age between these three groups, but when both age and proliferative
capacity were included in a multivariate Cox-regression, only the effect
of age remained signiﬁcant, indicating that this factor is themost impor-
tant predictor of survival.
3.4. All of the GC Lines Expressed SOX2 and NESTIN
Expression by 27 GC lines of the commonly used cell lineage
markers SOX2 (sex determining region Y (SRY)-box 2), NESTIN, GFAP
(glial ﬁbrillary acidic protein), OLIG2 (oligodendrocyte transcription
factor 2), S100B (S100 calcium binding protein B) and TUBB3 (beta 3
class III tubulin) was examined by immunostaining and Fig. 4A depicts
representative staining patterns for one cell line of each subtype.
SOX2, a marker of neural stem and progenitor cells (Graham et al.,
2003), was expressed by almost all of the cells in all lines stained
(Fig. 4B), indicating that an immature stem cell-like population of GCs
had been propagated. NESTIN, a stem- and progenitor cell marker
(Dahlstrand et al., 1992; Lendahl et al., 1990), was also expressed by
most of the cells in all lines (Fig. 4C). While the expression of SOX2
and NESTIN was highly uniform, expression of GFAP (Fig. 4D) and
OLIG2 (Fig. 4E) varied widely. Further, a large proportion of Mesenchy-
mal lines show a lower expression of Olig2 (Fig. S2A–B). The neuronal
lineage marker TUBB3 and the astrocytic marker S100B (Fig. 4A) were
expressed to varying extents within and between the GC lines, being
co-expressed in the same cells in approximately 80% of the cultures
and thereby displaying aberrant lineage commitment, a feature charac-
teristic of cancer stem cells (Galli et al., 2004).
3.5. Tumorigenicity of the GC Lines
To test the capacity of our GC lines to produce secondary tumors,
1 × 105 cells from 30 different GC lines (of which two, U3084MG and
U3086MGwere derived from the same patient) were injected intracra-
nially into NOD-SCID mice (Table S6). These animals were sacriﬁced
when they showed symptoms, or, otherwise, at 20 weeks after the in-
jection (Fig. 5A–D). Interestingly, all of the Proneural, Neural and Classi-
cal cell lines gave rise tomacroscopic tumors that could be visualized by
hematoxylin and eosin (H&E) staining, whereas only 7 out of the 17
Mesenchymal cell lines generated such tumors (Fig. 5D–E). To distin-
guish xenografted human tumor cells frommurine cells we stained tis-
sue sections with the human-speciﬁc STEM121 antibody (Fig. 5F–G and
S3A–C, lower panels), and found that this staining overlappedwell with
the H&E staining (Figs. 5F, S3A–C). At the same time we could detect
single human GCs in the brains of the mice injected with 8 of the cell
lines that did not generate macroscopic tumors (Fig. 5G, lower right
panel).
Mice with tumors caused by Proneural GC lines displayed the
shortest survival compared to mice injected with cells of the othersubtypes (Fig. 5H), with the most signiﬁcant difference being to brain
tumors caused by Mesenchymal GC lines. This goes well in line with
the higher proliferative capacity of Proneural lines (Fig. 3D) and the re-
duced survival of non-G-CIMP Proneural patients (Brennan et al., 2013),
suggesting a more aggressive GC phenotype in non-G-CIMP Proneural
GBM.
Twenty of the 30 GC lines gave rise to tumors that were often large,
cell-dense, diffuse and invasive within 20 weeks (Figs. 5F and S3A–C).
Their histopathology was similar to that of gliomas grades III–IV with
characteristic features such as cellular pleomorphism (Fig. S3D–G),
atypical nuclei (Fig. S3D–G), diffuse inﬁltration (Figs. S3A, S3C, S3D),
mitotic ﬁgures (Fig. S3E), increased vascularity (Fig. S3F) and in some
cases, pseudopalisading necroses (Fig. S3G). Some had spread diffusely
throughout the brain parenchyma (Fig. S3A), while others grew
expansively in nodular patterns, clearly demarcated from the normal
parenchyma (Fig. S3B). Although there were such differences between
GC lines, individual tumors derived from the same cell line exhibited
highly similar histopathology. These differences in tumorigenicity and
histopathology most likely reﬂect the extensive heterogeneity of
GBMs and indicate that we can maintain their distinct properties both
in vitro and in vivo.
The histopathology of a subset of these secondary tumors in NOD-
SCID mice was compared to that of the corresponding primary patient
tumor (Fig. 5I). Mitotic tumor cells (white arrows), and apoptotic cells
with condensed nuclei (white arrowheads) were numerous in both
types of tumors. With certain GC lines (e.g. U3047MG, U3021MG and
U3020MG) we observed striking similarities between the human GBM
and corresponding mouse tumor while others (e.g. U3004MG) were
less similar (Fig. 5I). To summarize, the xenografted tumors in mice
had the hallmarks of high-grade gliomas but did not always display
the same histopathology as the primary tumor from which the GC line
was isolated.
3.6. Genomic Similarity of the GC Lines to the TCGA GBM Cohort
Analysis of copy number aberration (CNA) in all of our 48 GC lines
employing Affymetrix Cytoscan HD arrays containing more than 2.6
million probes revealed changes characteristic of glioblastoma, such as
chromosome 7 gains and chromosome 10 losses, present in more than
70% of the lines (Fig. 6A). This pattern was strikingly similar to that of
the tumors in the TCGA cohort (Fig. 6B, Pearson correlation coefﬁcient
0.72 across the genome) indicating that, in terms of genomic aberra-
tions, our GC lines constitute a diverse and representative sampling of
human GBM. Focusing on regions known to be recurrently altered in
GBM, we analyzed the ampliﬁcation and deletion frequency in the sig-
niﬁcantly altered regions reported by Brennan et al. (Brennan et al.,
2013). Regions containing the CDKN2A, EGFR and PDGFRA loci, showed
no signiﬁcant difference in aberration frequency (Fig. 6C). Loci with a
signiﬁcant difference in alteration frequency included 3q26.33 (con-
taining SOX2) which was more frequently ampliﬁed in GC lines than
in the TCGA material (p b 0.01) and 17q11.2 (containing NF1) which
was alsomore frequently ampliﬁed (p b 0.001) (Fig. 6C). This discrepan-
cy could reﬂect differences between the sample populations, or an en-
richment of tumor cells in HGCC cultures. The HGCC and TCGA CNA
patterns were largely similar at the level of individual subtypes
(Table S7), with signiﬁcant differences only in 17q11.2 (p b 0.01),
3q13.31 (p b 0.05) and 3p21.31 (p b 0.05) which were more frequently
ampliﬁed in HGCC Mesenchymal samples when compared to TCGA
Mesenchymal samples (Table S8). The fact that most of the Mesenchy-
mal GC lines did not form intracranial tumors in the NOD-SCID mice
raised the concern that many of these lines might have originated
from normal (non-cancerous) cells. To examine this possibility, we
compared the CNA data for the GC lines that could (Fig. S4A) or could
not (Fig. S4B) formmacroscopic tumors and found highly similar geno-
mic aberrations between the groups, demonstrating that the GC lines
that did not form tumors were nonetheless also cancer cells.
Fig. 4. Expression of neural and glial proteinmarkers by the GC lines. (A) Representative double immunoﬂuorescence staining of cultured cells for SOX2 andGFAP, OLIG2 and NESTIN, and
S100B and TUBB3. Scale bar = 50 μm. (B–E). The percentage of cells in 27 GC lines staining positively for (B) SOX2, (C) NESTIN, (D) GFAP, and (E) OLIG2.
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To explore the degree to which the GC lines remained transcription-
ally stable under diverse experimental conditions, we transplanted
three different lines (U3020MG, U3047MG andU3065MG) intracranial-
ly to NOD-SCID mice; explanted the resulting tumors and cultured the
cells for two passages, and then isolated RNA from the cell line prior
to transplantation (U3020MG-p10, U3047MG-p7, U3065MG-p10),
from the xenograft tumor and from the explanted cells (Fig. 7A).
Transcript proﬁling followed by molecular subtype analysis (Fig. 7B)
and Isomap representation (Fig. 7C) revealed that the Proneural
U3047MG line remained Proneural throughout the entire experiment(Fig. 7B–C). The Mesenchymal U3020MG line changed to the Classical
subtype in the xenograft tumor and remained Classical in the explanted
cells (Fig. 7B–C). The other Mesenchymal line, U3065MG, changed to
the Proneural phenotype in the xenograft tumor, but reverted to Mes-
enchymal the explanted GCs (Fig. 7B–C).
Altogether, these ﬁndings conﬁrm to some extent the data by
Bhat et al. where Proneural GCs were found to be more transcrip-
tionally stable than Mesenchymal GCs when transferred from cul-
ture to xenograft (Bhat et al., 2013). The drift in subtype could
reﬂect a clonal selection similar to the mechanism of developing
drug resistance (Bhang et al., 2015), but could also be due to a differ-
ential sensitivity of the cells to respond to a newmicroenvironment,
Fig. 5. The tumorigenicity of the GC lines. (A–D) Kaplan–Meier graphs illustrating the survival of NOD-SCIDmice injected intracranially with GC lines of the (A) Proneural (PN), (B) Neural
(NL), (C) Classical (CL) and (D) Mesenchymal (MS) subtypes. (E) Summary of tumor formation and staining for STEM121 (human-speciﬁc). (F–G) H&E staining and immunostaining for
STEM121 in the brains of mice injectedwith theU3024MG (F) or U3034MG (G)Mesenchymal GC lines. Black scale bar= 500 μm,white scale bar= 50 μm. (H) Kaplan–Meier graph com-
paring survival ofNOD-SCIDmice injectedwithGC lines of different subtypes. (I) H&E stainings of secondary tumors inNOD-SCIDmice (left column) and thehuman tumor fromwhich the
cell line was derived (right column). Scale bar = 50 μm. See also Fig. S3.
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Fig. 6.Genomic similarity of the GC lines to the TCGAGBM tissue samples. Genomic copy number variation analysis in (A) the 48GC lines, and (B) 509 GBM samples from the TCGA tumor
tissue cohort. (C) CNA variation in the GC lines of different subtypes shows similar trends as the TCGAdata; the heatmap shows ampliﬁcations (red) and deletions (blue) for a selected set
of regions (rows) previously reported (Brennan et al., 2013). Signiﬁcant difference (Chi-squared p-value, Holm correction) in alteration frequency was found for 3q26.33 (containing the
SOX2 locus, p b 0.01) and 17q11.2 (containing NF1, p b 0.001) which was ampliﬁed at a higher frequency in our GC lines compared to TCGA.
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for two passages after the xenograft tumor was explanted. System-
atic analysis of the plasticity and genetic diversity of our GC lines
will be the subject of future work.4. Discussion
The development and pre-clinical validation of novel anti-cancer
drugs require scalable, representative, and reproducible experimental
Fig. 7. Stability of themolecular subtypes in GC cell line culture and in vivo. (A) Schematic overview of the procedure. (B)Molecular subtype based on gene expression as determinedwith
the Affymetrix Human Transcriptome Array 2.0. The proportion of times each cell line or tissue was assigned to the Mesenchymal (MS, red bars), Neural (NL, green bars), Proneural (PN,
magenta bars) or Classical (CL, blue bars) subtype is depicted by the bars, and the ﬁnal assignment is denoted to the right of the bars. (C) Isomap of samples from the analysis of subtype
stability with 529 TCGA GBM tissue samples as reference.
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connection include the collection of NCI-60 human tumor cell lines
(containing 6 GBM lines) (Scherf et al., 2000), the translational Cancer
Genomics program (Garnett et al., 2012), and the Broad-Novartis
Cancer Cell Line Encyclopedia (CCLE) (Barretina et al., 2012) which in-
cludes 62 GBM samples. All these initiatives involve cultures grown in
serum, which do not demonstrate the phenotypic properties of the
tumor of origin. Furthermore, the origin of several of the cell lines has
been questioned; in several instances STR proﬁling has revealed cross
contamination or misidentiﬁcation of established cell lines, including
several GBM lines (Capes-Davis et al., 2010). Finally, formost of the pub-
lically available cell lines associated clinical data are lacking, which fur-
ther reduces their value.
Since the initial reports on culturing human GC lines in serum-free
neural stem cell medium (Lee et al., 2006), several groups have demon-
strated the usefulness of this approach, where the phenotype of the cul-
tured cells resembles that of the tumor of origin (Balvers et al., 2013;
Fael Al-Mayhani et al., 2009; Meyer et al., 2015; Pollard et al., 2009).
However, to date these cultures have not been established with the in-
tention to be made publically available to researchers in general. Here,
we have established a biobank of 48 cell lines derived fromGBM tumors
(the HGCC resource, Table S2), employing the neurosphere assay and
the adherent monolayer protocol, two validated techniques for cultur-
ing GSCs. A large part of the HGCC panel is linked to the U-CAN biobank
initiative (www.u-can.uu.se), which, in addition to providing samples
of frozen tumor tissue and patient blood, makes annotated clinical
data for each patient available.
As a ﬁrst step, sphere formation to remove tissue debris and red
blood cells, as well as to enrich for GSCs was utilized (Fael Al-Mayhani
et al., 2009). Although this neurosphere technique has been successful
in establishing cultures with stem cell characteristics from malignant
brain tumors (Ignatova et al., 2002), it has certain limitations. If not
closely monitored neurospheres grow too large and begin to differenti-
ate (Suslov, 2002). Moreover, inadvertent fusion of spheres (Singec
et al., 2006) can contribute to an undesirable heterogeneity in sphere
size. Adherent cultures (Conti et al., 2005) allow the cells to beuniformly exposed to nutrients, oxygen and growth factors, in addition
to monitoring of individual cells. Therefore, we subsequently plated the
spheres onto laminin-coated dishes, thereby generating 53 expandable
cell lines from 94 surgical GBM samples (Table S1), of which 48 were
characterized in greater details (Table S2). The observation that patients
whose tumors produced sustainable cultures exhibited poorer survival
(Fig. 1A) shows that our culture conditions are appropriate for cells
from the more aggressive tumors, although we also have cell lines
from the tumors of long-term survivors (N2 years). A future challenge
will be to improve the development of sustainable cultures from youn-
ger patients in order to extend the coverage of GBM heterogeneity in
our biobank. Achieving this goal probably require extensive modiﬁca-
tion of the culture medium and solid substrate.
With few exceptions, our GC lines could be reliably classiﬁed with re-
spect to molecular subtype, with all four subtypes being represented at
about the same proportions as in the TCGA database. Because of the ex-
tensive intra-tumor heterogeneity of GBM tumors, with different samples
and even individual cells from the same tumor being of different subtypes
(Sottoriva et al., 2013), we anticipated that our GC lines might differ phe-
notypically from the tumor of origin. Indeed, gene expression proﬁling
revealed that only 45% of these lines displayed the same subtype as the
tumor of origin, probably not only because of sample heterogeneity but
also due to the presence of non-neoplastic cells (inﬂammatory cells, reac-
tive astrocytes, vascular cells) in the tissue samples.
When subtype stability was tested in a small subset of GC lines
(Fig. 7), two out of three were found to change their subtype following
orthotopic xenotransplantation to NOD-SCID mice, although one of
these reverted to the original subtype after explantation. Thus, in addi-
tion to local heterogeneity of cells of a particular subtype at any given
timepoint, the proﬁle of RNA expression within a given cell population
can also alter. It is possible that in addition to tumor-stromal interac-
tions, the tumor microenvironment may not only facilitate progression
of GBM (Charles et al., 2011) but also inﬂuence classiﬁer gene expres-
sion that leads to a shift in subtype.
All of the cells in our GC lines express the stem cell markers NESTIN
and SOX2, indicating enrichment of GSCs in the cultures. This
Fig. 8.Overview of how the HGCC biobankwill support translational brain tumor research.We provide a large-scale, open access repository of patient-derived GBM cell culturesmatched
with clinical data (A) that enables accurate cell-based modeling of GBM diversity. Coupled to the cell bank wemake available a user-friendly data repository (B) to support users in their
selection ofHGCC lineswith particular properties, molecular subtype ormarker expression.We foresee amultitude of applications (C), such as single/oligo cell line studies of e.g. candidate
genes andmechanisms in vitro and in vivo (xenograft modeling), multi-cell line studies, e.g. screening for inhibitory compounds or siRNAs, and data mining in relation to other publically
available data sets.
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lines tested gave rise to large tumors that inﬁltrated the brain tissue, in-
cluding the contralateral hemisphere. Since the invasive character of
GBM is such a key factor in its dismal outcome, human cell lines that
mimic this behavior in the mouse brain are potentially highly useful
tools. Interestingly, most of the Mesenchymal GC lines injected did not
give rise to macroscopic tumors after 20 weeks, even though these
were conﬁrmed to be tumor cells by CNA (Fig. S4). Instead, we detected
viable human GCs, often diffusely spread, in most of the brains from
these mice (Fig. 5G). The observation that all the cell lines that failed
to produce a tumor were Mesenchymal suggests that this subtype
may contain phenotypically distinct subgroups that should be explored.
Other challenges will be to determine whether, given enough time,
these scattered human GCs can give rise to GBM in mice, and whether
they represent a distinct subset of the parental cell line.
In summary,we have created a highly relevant biobank of humanGC
lines that retain the most prominent characteristics of their original tu-
mors. Our goal is to make this an open-source repository that will en-
able stratiﬁed studies of disease mechanisms and facilitate the
development of novel treatment strategies. All ethical, legal and practi-
cal matters regarding sharing the cell lines are in place. A number of the
HGCC cell lines have already been used in different types of investiga-
tions ranging from basic understanding of GBM biology (Savary et al.,
2013; Babateen et al., 2015; Wee et al., 2014), drug screening
(Schmidt et al., 2013), drug discovery (Kitambi et al., 2014) and devel-
opment of vectors for gene therapy (Yu et al., 2013). TheHGCC resource
enables accurate cell-based modeling of GBM and is connected with a
database (www.hgcc.se), which provides current molecular, phenotyp-
ic and clinical data on each cell line in a searchable fashion (Fig. 8A–B).
This website will be continuously updated with links to future datasets.
Speciﬁc ways in which the cell repository can be used as a resource for
translational studies include i) selection of individual lines for in vivo
modeling of GBM, ii) the use of cell line panels for comparative testing
of compounds or candidate genes; or, iii) integrated analysis of HGCC
lines in conjunction with public datasets, for instance to relate variabil-
ity in tumor cells to that obtained in tumor tissue repositories such as
TCGA (Fig. 8C).
GBM is only one of several types of cancer for which current therapy
is inadequate and we hope that our present initiative will encourage
other investigators to emulate and improve upon our model.
Author Contributions
Contributions are only speciﬁed for each ﬁrst, second and last au-
thor. L.U., B.W., K.F.N., and S.N. conceived the project and designedexperiments. Y.X., T.B., and Y.J. designed and performed in vitro and
in vivo experiments and analyzed data. P.J., V.D.M., and S.N. performed
molecular proﬁling, genomic characterization and data analyses. P.J.
established the web resource. All ﬁrst and last authors wrote the
manuscript.
Acknowledgments
This studywas supported by grants from the Swedish Cancer Society
(#140787, #140743, #140678, #140385), the Swedish Research Coun-
cil (#K2015-99X-20774-08-4, #K2014-61X-15274-07-4, #K2013-62X-
21473-04-3), and the Knut and the Alice Wallenberg Foundation
(#KAW2013.0280). We thank Drs. Cameron Brennan and Jason Huse,
Memorial Sloan-Kettering Cancer Center, for sharing the NanoString
probe set with us. Array measurements, normalization and copy num-
ber identiﬁcation were performed at the SciLifeLab Uppsala Array and
Analysis Facility. Sequencing of the IDH1 locuswas performed at theNa-
tional Genomics Infrastructure and SciLifeLab Uppsala Genome Center.
The tissue slides were scanned at the SciLifeLab Tissue Proﬁling Facility
in Uppsala.
Appendix A. Supplementary Data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.08.026.
References
Babateen, O., Jin, Z., Bhandage, A., Korol, S.V., Westermark, B., Forsberg Nilsson, K.,
Uhrbom, L., Smits, A., Birnir, B., 2015. Etomidate, propofol and diazepam potentiate
GABA-evoked GABAA currents in a cell line derived from human glioblastoma. Eur.
J. Pharmacol. 748, 101–107.
Balvers, R.K., Kleijn, A., Kloezeman, J.J., French, P.J., Kremer, A., Van Den Bent, M.J., Dirven,
C.M., Leenstra, S., Lamfers, M.L., 2013. Serum-free culture success of glial tumors is re-
lated to speciﬁc molecular proﬁles and expression of extracellular matrix-associated
gene modules. Neuro Oncol. 15, 1684–1695.
Bao, S., Wu, Q., Mclendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W., Bigner,
D.D., Rich, J.N., 2006. Glioma stem cells promote radioresistance by preferential acti-
vation of the DNA damage response. Nature 444, 756–760.
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J.,
Lehar, J., Kryukov, G.V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M.F.,
Monahan, J.E., Morais, P., Meltzer, J., Korejwa, A., Jane-Valbuena, J., Mapa, F.A.,
Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I.H., Cheng, J., Yu, G.K.,
Yu, J., Aspesi, P., Jr., De Silva, M., Jagtap, K., Jones, M.D., Wang, L., Hatton, C.,
Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R.C., Liefeld, T.,
Macconaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J.P., Gabriel, S.B., Getz, G.,
Ardlie, K., Chan, V., Myer, V.E., Weber, B.L., Porter, J., Warmuth, M., Finan, P., Harris,
J.L., Meyerson, M., Golub, T.R., Morrissey, M.P., Sellers, W.R., Schlegel, R., Garraway,
L.A., 2012. The Cancer Cell Line Encyclopedia enables predictivemodelling of antican-
cer drug sensitivity. Nature 483, 603–607.
1362 Y. Xie et al. / EBioMedicine 2 (2015) 1351–1363Beier, D., Hau, P., Proescholdt, M., Lohmeier, A., Wischhusen, J., Oefner, P.J., Aigner, L.,
Brawanski, A., Bogdahn, U., Beier, C.P., 2007. CD133(+) and CD133(−)
glioblastoma-derived cancer stem cells show differential growth characteristics and
molecular proﬁles. Cancer Res. 67, 4010–4015.
Bhang, H.E.C., Ruddy, D.A., Radhakrishna, V.K., Caushi, J.X., Zhao, R., Hims, M.M., Singh,
A.P., Kao, I., Rakiec, D., Shaw, P., Balak, M., Raza, A., Ackley, E., Keen, N., Schlabach,
M.R., Palmer, M., Leary, R.J., Chiang, D.Y., Sellers, W.R., Michor, F., Cooke, V.G., Korn,
J.M., Stegmeier, F., 2015. Studying clonal dynamics in response to cancer therapy
using high-complexity barcoding. Nat. Med. 21, 440-448.
Bhat, K.P., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K.,
Hollingsworth, F., Wani, K., Heathcock, L., James, J.D., Goodman, L.D., Conroy, S.,
Long, L., Lelic, N., Wang, S., Gumin, J., Raj, D., Kodama, Y., Raghunathan, A., Olar, A.,
Joshi, K., Pelloski, C.E., Heimberger, A., Kim, S.H., Cahill, D.P., Rao, G., Den Dunnen,
W.F., Boddeke, H.W., Phillips, H.S., Nakano, I., Lang, F.F., Colman, H., Sulman, E.P.,
Aldape, K., 2013. Mesenchymal differentiation mediated by NF-kappaB promotes ra-
diation resistance in glioblastoma. Cancer Cell 24, 331–346.
Bleau, A.M., Hambardzumyan, D., Ozawa, T., Fomchenko, E.I., Huse, J.T., Brennan, C.W.,
Holland, E.C., 2009. PTEN/PI3K/Akt pathway regulates the side population phenotype
and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226–235.
Brennan, C.W., Verhaak, R.G.W., McKenna, A., Campos, B., Noushmehr, H., Salama, S.R.,
Zheng, S.Y., Chakravarty, D., Sanborn, J.Z., Berman, S.H., Beroukhim, R., Bernard, B.,
WU, C.J., Genovese, G., Shmulevich, I., Barnholtz-Sloan, J., Zou, L.H., Vegesna, R.,
Shukla, S.A., Ciriello, G., Yung, W.K., Zhang, W., Sougnez, C., Mikkelsen, T., Aldape,
K., Bigner, D.D., Van Meir, E.G., Prados, M., Sloan, A., Black, K.L., Eschbacher, J.,
Finocchiaro, G., Friedman, W., Andrews, D.W., Guha, A., Iacocca, M., O'neill, B.P.,
Foltz, G., Myers, J., Weisenberger, D.J., Penny, R., Kucherlapati, R., Perou, C.M., Hayes,
D.N., Gibbs, R., Marra, M., Mills, G.B., Lander, E., Spellman, P., Wilson, R., Sander, C.,
Weinstein, J., Meyerson, M., Gabriel, S., Laird, P.W., Haussler, D., Getz, G., Chin, L., Net-
work, T.R., 2013. The somatic genomic landscape of glioblastoma. Cell 155, 462–477.
Capes-Davis, A., Theodosopoulos, G., Atkin, I., Drexler, H.G., Kohara, A., Macleod, R.A.,
Masters, J.R., Nakamura, Y., Reid, Y.A., Reddel, R.R., Freshney, R.I., 2010. Check your
cultures! A list of cross-contaminated or misidentiﬁed cell lines. Int. J. Cancer 127,
1–8.
Charles, N.A., Holland, E.C., Gilbertson, R., Glass, R., Kettenmann, H., 2011. The brain tumor
microenvironment. Glia 59, 1169–1180.
Chen, J., Li, Y., Yu, T.S., Mckay, R.M., Burns, D.K., Kernie, S.G., Parada, L.F., 2012. A restricted
cell population propagates glioblastoma growth after chemotherapy. Nature 488,
522–526.
Conti, L., Pollard, S.M., Gorba, T., Reitano, E., Toselli, M., Biella, G., Sun, Y., Sanzone, S., Ying,
Q.-L., Cattaneo, E., Smith, A., 2005. Niche-independent symmetrical self-renewal of a
mammalian tissue stem cell. PLoS Biol. 3, e283.
Dahlstrand, J., Collins, V.P., Lendahl, U., 1992. Expression of the class VI intermediate
ﬁlament nestin in human central nervous system tumors. Cancer Res. 52,
5334–5341.
Dolecek, T.A., Propp, J.M., Stroup, N.E., Kruchko, C., 2012. CBTRUS statistical report: prima-
ry brain and central nervous system tumors diagnosed in the United States in
2005–2009. Neuro-Oncology 14 (Suppl. 5), v1–v49.
Fael Al-mayhani, T.M., Ball, S.L.R., Zhao, J.-W., Fawcett, J., Ichimura, K., Collins, P.V., Watts,
C., 2009. An efﬁcient method for derivation and propagation of glioblastoma cell lines
that conserves the molecular proﬁle of their original tumours. J. Neurosci. Methods
176, 192–199.
Galli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C.,
Dimeco, F., Vescovi, A., 2004. Isolation and characterization of tumorigenic, stem-
like neural precursors from human glioblastoma. Cancer Res. 64, 7011–7021.
Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger,
P., Thompson, I.R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R.J.,
Bignell, G.R., Tam, A.T., Davies, H., Stevenson, J.A., Barthorpe, S., Lutz, S.R., Kogera, F.,
Lawrence, K., McLaren-Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H.,
Richardson, L., Zhou, W., Jewitt, F., Zhang, T., O'Brien, P., Boisvert, J.L., Price, S., Hur,
W., Yang, W., Deng, X., Butler, A., Choi, H.G., Chang, J.W., Baselga, J., Stamenkovic, I.,
Engelman, J.A., Sharma, S.V., Delattre, O., Saez-Rodriguez, J., Gray, N.S., Settleman, J.,
Futreal, P.A., Haber, D.A., Stratton, M.R., Ramaswamy, S., McDermott, U., Benes, C.H.,
2012. Systematic identiﬁcation of genomic markers of drug sensitivity in cancer
cells. Nature 483, 570–575.
Graham, V., Khudyakov, J., Ellis, P., Pevny, L., 2003. SOX2 functions to maintain neural pro-
genitor identity. Neuron 39, 749–765.
Hemmati, H.D., Nakano, I., Lazareff, J.A., Masterman-Smith, M., Geschwind, D.H., Bronner-
Fraser, M., Kornblum, H.I., 2003. Cancerous stem cells can arise from pediatric brain
tumors. Proc. Natl. Acad. Sci. U. S. A. 100, 15178–15183.
Ignatova, T.N., Kukekov, V.G., Laywell, E.D., Suslov, O.N., Vrionis, F.D., Steindler, D.A., 2002.
Human cortical glial tumors contain neural stem-like cells expressing astroglial and
neuronal markers in vitro. Glia 39, 193–206.
James, G., Witten, D., Hastie, T., Tibshirani, R., 2013. An Introduction to Statistical Learning:
With Applications in R. Springer, New York.
Joo, K.M., Kim, J., Jin, J., Kim, M., Seol, H.J., Muradov, J., Yang, H., Choi, Y.L., Park, W.Y., Kong,
D.S., Lee, J.I., Ko, Y.H., Woo, H.G., Lee, J., Kim, S., Nam, D.H., 2013. Patient-speciﬁc
orthotopic glioblastoma xenograft models recapitulate the histopathology and biolo-
gy of human glioblastomas in situ. Cell Rep. 3, 260–273.
Kastenhuber, E.R., Huse, J.T., Berman, S.H., Pedraza, A., Zhang, J., Suehara, Y., Viale, A.,
Cavatore, M., Heguy, A., Szerlip, N., Ladanyi, M., Brennan, C.W., 2014. Quantitative as-
sessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas:
their prevalence and molecular correlates. Acta Neuropathol. 127, 747–759.
Kitambi, S.S., Toledo, E.M., Usoskin, D., Wee, S., Harisankar, A., Svensson, R., Sigmundsson,
K., Kalderen, C., Niklasson, M., Kundu, S., Aranda, S., Westermark, B., Uhrbom, L.,
Andang, M., Damberg, P., Nelander, S., Arenas, E., Artursson, P., Walfridsson, J.,
Forsberg, Nilsson K., Hammarstrom, L.G., Ernfors, P., 2014. Vulnerability ofglioblastoma cells to catastrophic vacuolization and death induced by a small mole-
cule. Cell 157, 313–328.
Laks, D.R., Masterman-Smith, M., Visnyei, K., Angenieux, B., Orozco, N.M., Foran, I., Yong,
W.H., Vinters, H.V., Liau, L.M., Lazareff, J.A., Mischel, P.S., Cloughesy, T.F., Horvath, S.,
Kornblum, H.I., 2009. Neurosphere formation is an independent predictor of clinical
outcome in malignant glioma. Stem Cells 27, 980–987.
Lathia, J.D., Gallagher, J., Heddleston, J.M., Wang, J., Eyler, C.E., Macswords, J., Wu, Q.,
Vasanji, A., Mclendon, R.E., Hjelmeland, A.B., Rich, J.N., 2010. Integrin alpha 6 regu-
lates glioblastoma stem cells. Cell Stem Cell 6, 421–432.
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N.M., Pastorino, S., Purow, B.W.,
Christopher, N., Zhang, W., Park, J.K., Fine, H.A., 2006. Tumor stem cells derived
from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype
and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9,
391–403.
Lendahl, U., Zimmerman, L.B., McKay, R.D., 1990. CNS stem cells express a new class of in-
termediate ﬁlament protein. Cell 60, 585–595.
Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer,
B.W., Kleihues, P., 2007. The 2007 WHO classiﬁcation of tumours of the central ner-
vous system. Acta Neuropathol. 114, 97–109.
Mahesparan, R., Read, T.-A., Lund-Johansen, M., Skaftnesmo, K., Bjerkvig, R., Engebraaten,
O., 2003. Expression of extracellular matrix components in a highly inﬁltrative in vivo
glioma model. Acta Neuropathol. 105, 49–57.
Mayrhofer, M., Dilorenzo, S., Isaksson, A., 2013. Patchwork: allele-speciﬁc copy number
analysis of whole-genome sequenced tumor tissue. Genome Biol. 14, R24.
Meyer, M., Reimand, J., Lan, X., Head, R., Zhu, X., Kushida, M., Bayani, J., Pressey, J.C., Lionel,
A.C., Clarke, I.D., Cusimano, M., Squire, J.A., Scherer, S.W., Bernstein, M., Woodin, M.A.,
Bader, G.D., Dirks, P.B., 2015. Single cell-derived clonal analysis of human glioblasto-
ma links functional and genomic heterogeneity. Proc. Natl. Acad. Sci. U. S. A. 112,
851–856.
Nilsson, J., Fioretos, T., Hoglund, M., Fontes, M., 2004. Approximate geodesic dis-
tances reveal biologically relevant structures in microarray data. Bioinformatics
20, 874–880.
Noushmehr, H., Weisenberger, D.J., Diefes, K., Phillips, H.S., Pujara, K., Berman, B.P.,
Pan, F., Pelloski, C.E., Sulman, E.P., Bhat, K.P., Verhaak, R.G.W., Hoadley, K.A.,
Hayes, D.N., Perou, C.M., Schmidt, H.K., Ding, L., Wilson, R.K., Van Den Berg, D.,
Shen, H., Bengtsson, H., Neuvial, P., Cope, L.M., Buckley, J., Herman, J.G., Baylin,
S.B., Laird, P.W., Aldape, K., Network, C.G.A.R., 2010. Identiﬁcation of a CpG island
methylator phenotype that deﬁnes a distinct subgroup of glioma. Cancer Cell 17,
510–522.
Ogden, A.T., Waziri, A.E., Lochhead, R.A., Fusco, D., Lopez, K., Ellis, J.A., Kang, J., Assanah, M.,
Mckhann, G.M., Sisti, M.B., McCormick, P.C., Canoll, P., Bruce, J.N., 2008. Identiﬁcation
of AB25 + CD133-tumor-initiating cells in adult human gliomas. Neurosurgery 62,
505–515.
Ostrom, Q.T., Gittleman, H., Liao, P., Rouse, C., Chen, Y., Dowling, J., Wolinsky, Y., Kruchko,
C., Barnholtz-Sloan, J., 2014. CBTRUS statistical report: primary brain and central ner-
vous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol.
Suppl. 4, iv1–iv63.
Patel, A.P., Tirosh, I., Trombetta, J.J., Shalek, A.K., Gillespie, S.M., Wakimoto, H., Cahill, D.P.,
Nahed, B.V., Curry, W.T., Martuza, R.L., Louis, D.N., Rozenblatt-Rosen, O., Suva, M.L.,
Regev, A., Bernstein, B.E., 2014. Single-cell RNA-seq highlights intratumoral heteroge-
neity in primary glioblastoma. Science 344, 1396–1401.
Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra, A., Nigro,
J.M., Colman, H., Soroceanu, L., Williams, P.M., Modrusan, Z., Feuerstein, B.G., Aldape,
K., 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a
pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9,
157–173.
Pollard, S.M., Yoshikawa, K., Clarke, I.D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head,
R., Lee, M., Bernstein, M., Squire, J.A., Smith, A., Dirks, P., 2009. Glioma stem cell lines
expanded in adherent culture have tumor-speciﬁc phenotypes and are suitable for
chemical and genetic screens. Cell Stem Cell 4, 568–580.
Pontén, J., Macintyre, E.H., 1968. Long term culture of normal and neoplastic human glia.
Acta Pathol. Microbiol. Scand. 74, 465–486.
Savary, K., Caglayan, D., Caja, L., Tzavlaki, K., Bin Nayeem, S., Bergstrom, T., Jiang, Y.,
Uhrbom, L., Forsberg-Nilsson, K., Westermark, B., Heldin, C.H., Ferletta, M.,
Moustakas, A., 2013. Snail depletes the tumorigenic potential of glioblastoma. Onco-
gene 32, 5409–5420.
Scherf, U., Ross, D.T., Waltham, M., Smith, L.H., Lee, J.K., Tanabe, L., Kohn, K.W., Reinhold,
W.C., Myers, T.G., Andrews, D.T., Scudiero, D.A., Eisen, M.B., Sausville, E.A., Pommier,
Y., Botstein, D., Brown, P.O., Weinstein, J.N., 2000. A gene expression database for
the molecular pharmacology of cancer. Nat. Genet. 24, 236–244.
Schmidt, L., Kling, T., Monseﬁ, N., Olsson, M., Hansson, C., Baskaran, S., Lundgren, B.,
Martens, U., Haggblad, M., Westermark, B., Forsberg Nilsson, K., Uhrbom, L.,
Karlsson-Lindahl, L., Gerlee, P., Nelander, S., 2013. Comparative drug pair screening
across multiple glioblastoma cell lines reveals novel drug–drug interactions. Neuro
Oncol. 15, 1469–1478.
Singec, I., Knoth, R., Meyer, R.P., Maciaczyk, J., Volk, B., Nikkhah, G., Frotscher, M., Snyder,
E.Y., 2006. Deﬁning the actual sensitivity and speciﬁcity of the neurosphere assay in
stem cell biology. Nat. Methods 3, 801–806.
Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., Dirks, P.B., 2003.
Identiﬁcation of a cancer stem cell in human brain tumors. Cancer Res. 63,
5821–5828.
Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M.,
Cusimano, M.D., Dirks, P.B., 2004. Identiﬁcation of human brain tumour initiating
cells. Nature 432, 396–401.
Son, M.J., Woolard, K., Nam, D.-H., Lee, J., Fine, H.A., 2009. SSEA-1 is an enrichment marker
for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4, 440–452.
1363Y. Xie et al. / EBioMedicine 2 (2015) 1351–1363Sottoriva, A., Spiteri, I., Piccirillo, S.G., Touloumis, A., Collins, V.P., Marioni, J.C., Curtis, C.,
Watts, C., Tavare, S., 2013. Intratumor heterogeneity in human glioblastoma reﬂects
cancer evolutionary dynamics. Proc. Natl. Acad. Sci. U. S. A. 110, 4009–4014.
Stupp, R., Mason, W.P., Van Den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J.B.,
Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C.,
Ludwin, S.K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J.G., Eisenhauer, E.,
Mirimanoff, R.O., European Organisation For Research And Treatment Of Cancer
Brain Tumor And Radiotherapy Groups & National Cancer Institute Of Canada Clinical
Trials Group, 2005. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N. Engl. J. Med. 352, 987–996.
Suslov, O.N., 2002. Neural stem cell heterogeneity demonstrated by molecular phenotyp-
ing of clonal neurospheres. Proc. Natl. Acad. Sci. 99, 14506–14511.
Tenenbaum, J.B., De Silva, V., Langford, J.C., 2000. A global geometric framework for non-
linear dimensionality reduction. Science 290, 2319–2323.
Verhaak, R.G.W., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R.,
Ding, L., Golub, T., Mesirov, J.P., Alexe, G., Lawrence, M., O'kelly, M., Tamayo, P.,
Weir, B.A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H.S., Hodgson, J.G.,
James, C.D., Sarkaria, J.N., Brennan, C., Kahn, A., Spellman, P.T., Wilson, R.K., Speed,T.P., Gray, J.W., Meyerson, M., Getz, G., Perou, C.M., Hayes, D.N., 2010. Integrated ge-
nomic analysis identiﬁes clinically relevant subtypes of glioblastoma characterized
by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110.
Wee, S., Niklasson, M., Marinescu, V.D., Segerman, A., Schmidt, L., Hermansson, A., Dirks,
P., Forsberg-Nilsson, K., Westermark, B., Uhrbom, L., Linnarsson, S., Nelander, S.,
Andang, M., 2014. Selective calcium sensitivity in immature glioma cancer stem
cells. PLoS One 9, e115698.
Weller, M., Wick, W., Von Deimling, A., 2011. Isocitrate dehydrogenase mutations: a chal-
lenge to traditional views on the genesis and malignant progression of gliomas. Glia
59, 1200–1204.
Westermark, B., Ponten, J., Hugosson, R., 1973. Determinants for the establishment of per-
manent tissue culture lines from human gliomas. Acta Pathol. Microbiol. Scand. A 81,
791–805.
Yu, D., Jin, C., Ramachandran, M., Xu, J., Nilsson, B., Korsgren, O., Le Blanc, K., Uhrbom, L.,
Forsberg-Nilsson, K., Westermark, B., Adamson, R., Maitland, N., Fan, X.L., Essand,
M., 2013. Adenovirus serotype 5 vectors with Tat-PTD modiﬁed hexon and serotype
35 ﬁber show greatly enhanced transduction capacity of primary cell cultures. PLoS
One 8.
